ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Foghorn Therapeutics Inc

Foghorn Therapeutics Inc (FHTX)

7.63
0.57
(8.07%)
Closed October 13 3:00PM
7.63
0.00
(0.00%)
After Hours: 3:17PM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
7.63
Bid
7.50
Ask
8.00
Volume
127,517
7.03 Day's Range 7.64
2.70 52 Week Range 10.25
Market Cap
Previous Close
7.06
Open
7.05
Last Trade
1
@
7.5
Last Trade Time
Financial Volume
US$ 944,866
VWAP
7.4097
Average Volume (3m)
155,864
Shares Outstanding
55,328,655
Dividend Yield
-
PE Ratio
-4.29
Earnings Per Share (EPS)
-1.78
Revenue
34.16M
Net Profit
-98.43M

About Foghorn Therapeutics Inc

Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various compo... Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
-
Foghorn Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker FHTX. The last closing price for Foghorn Therapeutics was US$7.06. Over the last year, Foghorn Therapeutics shares have traded in a share price range of US$ 2.70 to US$ 10.25.

Foghorn Therapeutics currently has 55,328,655 shares outstanding. The market capitalization of Foghorn Therapeutics is US$390.62 million. Foghorn Therapeutics has a price to earnings ratio (PE ratio) of -4.29.

FHTX Latest News

Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors

Primary target patient population for the FHD-909 Phase 1 trial is non-small cell lung cancer (NSCLC) Lilly leads the clinical development of the Phase 1 trial Foghorn’s selective SMARCA2...

Invaio Sciences Appoints André Andonian as Chairman of the Board of Directors

Invaio Sciences Appoints André Andonian as Chairman of the Board of Directors PR Newswire CAMBRIDGE, Mass., Oct. 3, 2024 CAMBRIDGE, Mass., Oct. 3, 2024 /PRNewswire/ -- Invaio Sciences, a Flagship...

Foghorn Therapeutics to Participate in the BMO Oncology Summit

CAMBRIDGE, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.22.691790040387.438.096.941194127.53624508CS
4-1.42-15.69060773489.0510.256.942298509.20520828CS
121.5625.70016474466.0710.254.871558648.33931683CS
260.476.564245810067.1610.254.771226157.30648901CS
523.86102.3872679053.7710.252.71252326.17749197CS
156-5.59-42.284417549213.2224.342.714775111.50265742CS
260-10.49-57.891832229618.1228.2652.713969112.20319566CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CAMPCAMP4 Therapeutics Corporation
 10.75
(2,587.50%)
378.47k
TWGTop Wealth Group Holding Ltd
US$ 7.14
(233.64%)
154.23M
NIVFNewGenIvf Group Ltd
US$ 0.98
(63.42%)
58.51M
ATIFATIF Holdings Ltd
US$ 1.235
(58.33%)
3.85M
VERBVerb Technology Company Inc
US$ 7.91
(51.82%)
15.55M
BYUBAIYU Holdings Inc
US$ 0.299
(-35.28%)
10.99M
TURBTurbo Energy SA
US$ 2.1511
(-29.01%)
2.83M
SMSTDefiance Daily Target 1.5X Short MSTR ETF
US$ 7.898
(-23.62%)
984.8k
VEEAVeea Inc
US$ 3.27
(-23.24%)
279.91k
INHDInno Holdings Inc
US$ 3.74
(-22.41%)
243.8k
JTAIJet AI Inc
US$ 0.1009
(23.50%)
335.77M
CDTConduit Pharmaceuticals Inc
US$ 0.116
(13.28%)
257.95M
NVDANVIDIA Corporation
US$ 134.80
(-0.01%)
161.76M
LUXHLuxUrban Hotels Inc
US$ 0.0532
(5.35%)
159.27M
TWGTop Wealth Group Holding Ltd
US$ 7.14
(233.64%)
149.99M

FHTX Discussion

View Posts
PonkenPlonken PonkenPlonken 4 weeks ago
about to make a 52w high
👍️0
PonkenPlonken PonkenPlonken 1 month ago
here it comes
👍️0
PonkenPlonken PonkenPlonken 2 months ago
BRM and BRG1 ..... Chromatin biology..... FHTX can help 500000 patients.
They all claim it but this platform works.
👍️0
PonkenPlonken PonkenPlonken 2 months ago
FHTX is one of Flagships exemplary projects.... LLY certainly thought so. They put a lot of $ on the table given FHTX was still an infant. They wanted this for themselves!
380mn upfront - say what?? there are also 1.3bn in milestones..... huge TAM @ 13bn $.... Company raised 103mn in May 2024...
Sources linked below. Money goes where it receives the most love.


"Establishes co-development and co-commercialization agreement on Foghorn's selective BRM program and an additional undisclosed program
Collaboration includes three additional discovery programs
Foghorn to receive $300 million upfront and an equity investment by Lilly of $80 million at $20 per share"
https://investor.lilly.com/news-releases/news-release-details/lilly-and-foghorn-announce-strategic-collaboration-novel
👍️0
Monksdream Monksdream 6 months ago
FHTX under $10
👍️0
HoldEm777 HoldEm777 3 years ago
Dip buy opportunity on low volume.
👍️0
HoldEm777 HoldEm777 3 years ago
Very close to next leg up it seems. Trades tight.
👍️0
TheFinalCD TheFinalCD 3 years ago
wow CONGRATS


what a day

FHTX
👍️0
crudeoil24 crudeoil24 3 years ago
20.34 in AH.
👍️0
crudeoil24 crudeoil24 3 years ago
FHTX up 57% @ 18.85 > surging into closing bell.
👍️0
TheFinalCD TheFinalCD 3 years ago
thanks I traded them...

lol

👍️0
crudeoil24 crudeoil24 3 years ago
Under the Stock Purchase Agreement, the Company has agreed to sell 4,000,000 shares of Common Stock (the “Shares”) to Lilly at $20.00 per share, for an aggregate purchase price of $80,000,000, on December 10, 2021 (the “SPA Closing”). In accordance with the Stock Purchase Agreement, the Company has amended its Amended and Restated Investors’ Rights Agreement, as previously amended (the “Investors’ Rights Agreement”), to provide Lilly with certain registration rights, including (i) the right to request that the Company file a registration statement on Form S-3 with respect to the Shares under conditions described in the Investors’ Rights Agreement; and (ii) in the event that the Company proposes to register any securities under the Securities Act, the right to certain “piggyback” registration rights allowing Lilly to include its registrable securities in such registration, subject to certain marketing and other limitations. In addition, pursuant to the Stock Purchase Agreement, the Company is obligated to use commercially reasonable efforts to allow Lilly to participate in future offerings of shares of Common Stock in an amount equal to its pro rata ownership of Common Stock, subject to certain limitations and exceptions, which obligation expires if Lilly ceases to hold all of the Shares or does not fully participate up to its pro rata ownership in any such offering. Lilly also has agreed to certain restrictions regarding an acquisition of the Company until the earlier of 540 days from the SPA Closing or such time as Lilly holds less than 2% of the outstanding Common Stock
👍️0
crudeoil24 crudeoil24 3 years ago
BIGGEST VOLUME DAY EVER!
👍️0
crudeoil24 crudeoil24 3 years ago
Huge volume! 10M in first 30 minutes.
👍️0
crudeoil24 crudeoil24 3 years ago
17.76 > Working our way to a 20.00+ run. Solid fundamental & technical catalysts!
👍️0
crudeoil24 crudeoil24 3 years ago
That's a fantastic BUY. > Go FHTX.
👍️0
Surfacetite Surfacetite 3 years ago
Nice, loaded some 17.48.
👍️0
TheFinalCD TheFinalCD 3 years ago
FHTX i BOUGHT 4500 SHARES AVG 17.67 ON THAT DIP
👍️0
crudeoil24 crudeoil24 3 years ago
Sound the foghorn! > Tutes loading shares all day!

FHTX
👍️0
crudeoil24 crudeoil24 3 years ago
Loaded 17.11's > Going to run 20.00+ today.
👍️0
crudeoil24 crudeoil24 3 years ago
Amazing! Trading float is 17M according to MarketWatch.

FHTX
👍️0
TheFinalCD TheFinalCD 3 years ago
FHTX As part of the deal, Eli Lilly will pay $300 million upfront and make an equity investment in Foghorn of $80 million, priced at $20 a share

https://www.marketwatch.com/story/foghorn-therapeutics-shares-soar-26-premarket-on-news-of-cancer-collaboration-with-eli-lilly-2021-12-13?siteid=yhoof2

THANKS FOR MAKING THE BOARD

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167100165
👍️0
crudeoil24 crudeoil24 3 years ago
Foghorn Therapeutics Stock Surges After $1.5B Cancer Pact With Eli Lilly
8:57 am ET December 13, 2021 (Benzinga) Print
Loxo Oncology, an R&D group of Eli Lilly And Co (NYSE: LLY), and Foghorn Therapeutics Inc (NASDAQ: FHTX) have collaborated to create oncology medicines by applying Foghorn's Gene Traffic Control platform.

The collaboration includes a co-development and co-commercialization agreement for Foghorn's selective BRM oncology program and an additional undisclosed oncology target.
In addition, the collaboration includes three additional discovery programs using Foghorn's Gene Traffic Control platform.
Under the agreement terms, Foghorn will receive upfront consideration of $300 million in cash and an equity investment by Lilly of $80 million at $20 per share.
For the BRM-selective program and the additional undisclosed target program, Foghorn will lead discovery and early research activities.
Lilly will conduct development and commercialization activities with participation from Foghorn in operational activities and cost-sharing.
Foghorn and Lilly will share 50/50 in the U.S. economics, and Foghorn is eligible to receive royalties on ex-U.S. sales.
Foghorn will lead discovery and early research activities for the additional discovery programs, and it may receive up to a total of $1.3 billion in potential development and commercialization milestones.
Price Action: FHTX shares are up 37.6% at $16.50, LLY stock is up 0.35% at $245.00 during the premarket session on the last check Monday.
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
👍️0
crudeoil24 crudeoil24 3 years ago
Foghorn Therapeutics Inc. is focused on the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system. The Company's Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate and potentially drug targets within the system. It is initially focused on oncology. It is developing FHD-286, a selective, allosteric ATPase inhibitor, which is evaluating in separate Phase I studies in metastatic uveal melanoma and relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). It is also developing FHD-609, a protein degrader, to treat synovial sarcoma is in phase I study. The Company is also engaged in developing additional programs targeting populations that include selective BRM and selective ARID1B modulators. Foghorn Securities Corporation is its subsidiary.
👍️0

Your Recent History

Delayed Upgrade Clock